$PFE 📰 Phase 3 CLOVER Trial for Pfizer's Investigational Clostridioides Difficile Vaccine Indicates Strong Potential Effect in Reducing Duration and Severity of Disease Based on Secondary Endpoints



45 seconds delayed.